Natasha K. A. van Eijkelenburg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Natasha K. A. van Eijkelenburg has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Karin Petra Sabine Langenberg-Ververgaert
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
19 shared publications - Adela Cañete
Hospital Universitario y Politècnico La Fe, 46026 Valencia, Spain
17 shared publications - Alba Rubio-San-Simón
Hospital Infantil Universitario Niño Jesús
17 shared publications - Gudrun Schleiermacher
Institut Curie, Paris, France
17 shared publications - Guy Makin
Royal Manchester Children's Hospital, Manchester, United Kingdom
17 shared publications - Lynley V. Marshall
Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
17 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Dose Levels of Arm D and Probabilities of Toxicity at the End of Dose Escalation (n=24 Patients Evaluable for DLT) and after the Whole Study (n=65 Patients Evaluable for DLT)
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Dose Levels of Arm D and Probabilities of Toxicity at the End of Dose Escalation (n=24 Patients Evaluable for DLT) and after the Whole Study (n=65 Patients Evaluable for DLT)
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Somatic Driver Mutations (A), Focal Amplification/deletions (B) or Gene Fusions (C) and Germline Mutations (D) Detected in 65 Patients Explored in the Molecular Analysis.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Somatic Driver Mutations (A), Focal Amplification/deletions (B) or Gene Fusions (C) and Germline Mutations (D) Detected in 65 Patients Explored in the Molecular Analysis.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Comparison of Homologous Recombination Deficiency (HRD) Scores and Tumor Mutational Burden (TMB) Between Treatment Responders and Non-Responders.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Comparison of Homologous Recombination Deficiency (HRD) Scores and Tumor Mutational Burden (TMB) Between Treatment Responders and Non-Responders.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Representativeness of Study Participants
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Representativeness of Study Participants
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Progression Free Survival (PFS) and Overall Survival (OS) in Patients Treated in Arm D.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Progression Free Survival (PFS) and Overall Survival (OS) in Patients Treated in Arm D.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Dose Levels for Dose Escalation
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Dose Levels for Dose Escalation
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Pharmacogenetic Study Evaluating the Association Between 5 Genetic Variants and Dose-limiting Toxicity (DLT) (N=41).
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Pharmacogenetic Study Evaluating the Association Between 5 Genetic Variants and Dose-limiting Toxicity (DLT) (N=41).
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Objective Response Rates in 66 Patients Treated Overall and per Dose Escalation or Dose Expansion in Other Malignancies and Ewing Sarcoma.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Objective Response Rates in 66 Patients Treated Overall and per Dose Escalation or Dose Expansion in Other Malignancies and Ewing Sarcoma.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Purpose:Arm D of the AcSé-ESMART proof-of-concept phase I/II platform trial aimed to define the recommended phase II dose (RP2D), pharmacokinetics, activity, and biomarkers of the PARP inhibitor olaparib with irinotecan in pediatric patients with recurrent/refractory malignancies.Patients and Methods:Olaparib was administered orally twice daily on days 1 to 10 and irinotecan intravenously on days 4 to 8 of a 21-day cycle. Dose escalation followed the continuous reassessment method; activity was assessed in diverse tumor types (cohort 1) and Ewing sarcoma (cohort 2) according to a minimax Simon 2-stage design. Cohorts were enriched for alterations in homologous recombination repair (HRR) pathways.Results:Seventy patients (median age, 14.9 years; range, 5.0–23.8) were included, 34 with diverse tumor types (25 with HRR gene alterations) and 36 with Ewing sarcoma. Sixty-six patients received 348 treatment cycles (median, 2; range, 1–51) over four dose levels. Main toxicities were gastrointestinal and myelosuppression; the RP2D was olaparib 90 mg/m2 twice daily and irinotecan 20 mg/m2/day. Olaparib exposure in children was equivalent to that in adults. The overall response rate was 9.1% (cohort 1, 11.8%; cohort 2, 6.3%). Four patients with osteosarcoma, pineoblastoma, choroid plexus carcinoma, and neuroblastoma experienced a partial response and were treated for nine to 51 cycles. Two patients with Ewing sarcoma experienced a complete and a partial response for 10 and 42 cycles, respectively. Genetic analyses suggest a high aneuploidy score possibly associated with objective response and prolonged stable disease.Conclusions:Olaparib combined with irinotecan demonstrated activity in pediatric tumors, which was enriched among tumors that exhibited aneuploidy.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Purpose:Arm D of the AcSé-ESMART proof-of-concept phase I/II platform trial aimed to define the recommended phase II dose (RP2D), pharmacokinetics, activity, and biomarkers of the PARP inhibitor olaparib with irinotecan in pediatric patients with recurrent/refractory malignancies.Patients and Methods:Olaparib was administered orally twice daily on days 1 to 10 and irinotecan intravenously on days 4 to 8 of a 21-day cycle. Dose escalation followed the continuous reassessment method; activity was assessed in diverse tumor types (cohort 1) and Ewing sarcoma (cohort 2) according to a minimax Simon 2-stage design. Cohorts were enriched for alterations in homologous recombination repair (HRR) pathways.Results:Seventy patients (median age, 14.9 years; range, 5.0–23.8) were included, 34 with diverse tumor types (25 with HRR gene alterations) and 36 with Ewing sarcoma. Sixty-six patients received 348 treatment cycles (median, 2; range, 1–51) over four dose levels. Main toxicities were gastrointestinal and myelosuppression; the RP2D was olaparib 90 mg/m2 twice daily and irinotecan 20 mg/m2/day. Olaparib exposure in children was equivalent to that in adults. The overall response rate was 9.1% (cohort 1, 11.8%; cohort 2, 6.3%). Four patients with osteosarcoma, pineoblastoma, choroid plexus carcinoma, and neuroblastoma experienced a partial response and were treated for nine to 51 cycles. Two patients with Ewing sarcoma experienced a complete and a partial response for 10 and 42 cycles, respectively. Genetic analyses suggest a high aneuploidy score possibly associated with objective response and prolonged stable disease.Conclusions:Olaparib combined with irinotecan demonstrated activity in pediatric tumors, which was enriched among tumors that exhibited aneuploidy.